Key Takeaways
- The S&P/ASX 200 Health Care index has a 10-year compound annual growth rate (CAGR) of 11.9%. This consistently beats the broader S&P/ASX 200 benchmark return of 8.1%.
- The top 10 health stocks on the ASX account for 94% of the sector's total market value. This group is led by major players including CSL, Cochlear, and ResMed.
- The Australian life sciences ecosystem generates over $8 billion in annual revenue. It is supported by government R&D tax incentives and significant funding for biotechnology innovation.
- Investing in the rare disease market offers unique perks. These include faster routes to market and seven years of market exclusivity once a drug receives regulatory approval.
- Artificial Intelligence is reducing costs by shortening drug development times. It also helps healthcare systems manage labour shortages by improving hospital workflows and scheduling.
Historically, the ASX healthcare sector has delivered strong performance for investors. The S&P/ASX 200 Health Care index outperformed the benchmark S&P/ASX 200 index in seven of the past 10 years. It delivered a CAGR of 11.9% compared to 8.1%. As inflation rose, the ASX healthcare sector struggled. But come October 2023 signs of improving investor sentiment emerged.
Looking forward, the outlook feels very positive. Inflation has been sticky and interest rates higher for longer than forecast. As rates come down and economic conditions improve, money is expected to continue to flow into the stock market and the emerging healthcare space.
Government Support for Life Sciences and Biotech
The Australian life sciences ecosystem is worth more than $8 billion in annual revenue. It is projected to grow at 3% annually from 2021 to 2026. Australia’s medical and biotechnology sector has benefited from a multimillion-dollar windfall of government funding. There are also substantial tax breaks for companies investing in R&D. Globally, the sector is projected to be worth around US$3.44 trillion by 2030. The Federal Government is ensuring Australia will well and truly be at the party.
Market Milestones and Top ASX Health Stocks
As of June 2024 there were 147 companies with a market capitalisation of $236 billion or more on the ASX. The top 10 health stocks represent 94% of the total. These include blood products giant CSL, Cochlear, and ResMed. Seeking professional investment advisory services can help you identify which of these leaders fit your specific portfolio goals.
As macroeconomic and geopolitical factors impact equity markets, companies hitting major milestones are performing well. These milestones include receiving regulatory approval or achieving positive clinical results. Securing material sales orders also helps performance.
Those in hot spaces like radiopharmaceuticals are also performing strongly. Solid sales momentum and approaching profitability tend to move a share price higher. The lucrative rare diseases market is also getting plenty of attention. Investors are coming to understand the benefits of an orphan drug designation (ODD). In the US perks include increased access to the FDA and new drug application fee waivers. It also offers a potentially faster route to market and seven additional years of exclusivity once a drug is approved.
Strategic Re-rating and Increased M&A Activity
After an extended period of under-performance, 2024 has seen several companies refresh management teams and boards. Many have changed or refocused strategy in an attempt to revitalise investor interest. In most cases, shares are being positively re-rated.
On the M&A front, domestic and international activity has increased. Many larger pharmaceutical and medical device companies have strong post-Covid balance sheets. They are looking to bolster their portfolios. This means M&A activity will likely continue throughout 2024. This activity is a key factor to watch during your regular financial planning reviews.
The Rise of Artificial Intelligence in Healthcare
Artificial intelligence (AI) is also emerging as a theme for healthcare. The Albanese government is investing $30 million in improving access to health services. Healthcare has historically lagged in technology adoption. But the healthcare system’s inherent constraints offer a compelling case for a significant role for AI in the sector’s future.
Labour shortages and budgetary pressures are changing current practices. Software is being introduced to improve workflow and enhance scheduling. It also helps coordinate care and fortify data security. Also, drug development will likely benefit through shorter development times. Improved patient selection will result in reduced costs and increase the number of drugs in the pipeline.
Find a Healthcare Investment Specialist
The healthcare sector is complex and moves quickly based on clinical trials and regulatory shifts. Our analysts can help you navigate this space and identify the companies with the strongest growth potential. Find a Morgans adviser today to discuss your healthcare investment strategy.
Morgans clients receive exclusive insights such as access to the latest stock and sector coverage featured in the Month Ahead. Contact ustoday to begin your journey with Morgans.
Frequently Asked Questions
How has the ASX healthcare sector performed over the long term?
The ASX 200 Health Care index has outperformed the broader market for much of the last decade. It achieved an average annual growth rate of 11.9% over ten years. This compares to the 8.1% return seen in the standard ASX 200 index.
What are the largest healthcare companies on the ASX?
The sector is dominated by a few large companies. CSL is the largest, followed by other major names like Cochlear and ResMed. These three companies are global leaders in blood products, hearing implants, and sleep apnoea treatments.
Why are biotech companies receiving government funding?
The Australian government views life sciences as a high-growth industry. Funding and R&D tax incentives are designed to encourage innovation locally. This support helps companies manage the high costs of clinical trials and drug development.
How does AI improve healthcare for patients and investors?
AI helps patients by enabling faster drug discovery and better care coordination. For investors, AI represents a way to reduce the high failure rate of drug development. It also helps companies manage rising labour costs through automation and better scheduling.
What is an Orphan Drug Designation?
This is a special status given to drugs that treat rare diseases. It provides companies with financial incentives to develop these treatments. Benefits include tax credits for clinical testing and several years of exclusive rights to sell the drug without competition.
